Chemotherapy independently reduced the risk of cardiocerebrovascular disease-related mortality by 25% (sHR 0.75) compared to no chemotherapy in colorectal cancer patients aged 50 and older.
Cohort (n=136,095)
Yes
Does systemic chemotherapy reduce cardiocerebrovascular disease-related mortality in middle-aged and elderly patients with colorectal cancer?
In middle-aged and elderly patients with colorectal cancer, systemic chemotherapy is independently associated with a 25% reduction in cardiocerebrovascular disease-related mortality.
Effect estimate: sHR 0.75 (95% CI 0.71-0.79)
Absolute Event Rate: 3.75% vs 9.68%
p-value: p=<0.001
The impact of chemotherapy on cardiocerebrovascular disease (CCVD) outcomes in patients with colorectal cancer (CRC) remains insufficiently explored. This research aimed to clarify the association between chemotherapy and CCVD-related mortality in middle-aged and elderly CRC patients. CRC patients aged ≥ 50 years at diagnosis were identified from the Surveillance, Epidemiology, and End Results (SEER) database for the period 2010–2015. The primary outcome was CCVD-related mortality. Survival analyses included Kaplan-Meier (KM) curves to characterize CCVD-related survival patterns and multivariate competing risks regression analysis to evaluate the independent association between chemotherapy and CCVD-related mortality. Subgroup analyses and Fine-Gray competing risks models were additionally performed to enhance the robustness of study findings. A total of 136 095 CRC patients were included. KM analysis showed a significantly lower cumulative risk of CCVD-related mortality in chemotherapy treatment group than in non-chemotherapy treatment group. After adjusting for age, race, gender, primary tumor site, and tumor stage, multivariate competing risks regression analysis confirmed that chemotherapy was an independent protective factor against CCVD-related mortality (sHR = 0.75, 95% CI 0.71–0.79, P < 0.001). Subgroup analyses and Fine-Gray competing risks models further validated the robustness of chemotherapy’s beneficial effect on CCVD outcomes. Chemotherapy may serve as an independent protective factor against CCVD-related mortality in CRC patients. These findings can help alleviate concerns regarding chemotherapy-associated CCVD risk in CRC management and provide novel insights for clinical decision-making and future research.
Chen et al. (Sun,) conducted a cohort in Colorectal cancer (n=136,095). Chemotherapy vs. No chemotherapy was evaluated on Cardiocerebrovascular disease (CCVD)-related mortality (sHR 0.75, 95% CI 0.71-0.79, p=<0.001). Chemotherapy independently reduced the risk of cardiocerebrovascular disease-related mortality by 25% (sHR 0.75) compared to no chemotherapy in colorectal cancer patients aged 50 and older.